Alzheimer's Disease Screening in Outpatient Neurology
GIA® screens during rooming or in the waiting area before the neurologist enters — capturing structured cognitive, motor-speech, and behavioral biomarker data that the specialist reviews alongside the patient's history and exam. The 40-second conversation produces results in under two minutes, available in the EHR before the face-to-face portion of the visit begins.
Alzheimer’s disease and related dementias affect an estimated 6.9 million Americans age 65 and older as of 2024 — about 1 in 9 (10.9%) of US adults in that age group (Alzheimer’s Association, 2024 Facts and Figures). Clinical recognition of dementia in primary care has a sensitivity of 73.4% by clinician judgment, but recognition is documented in medical records only 37.9% of the time (Mitchell, Meader, Pentzek, Acta Psychiatrica Scandinavica 2011; meta-analysis of 15 dementia studies). Contemporary US Medicare data surface a different problem: dementia is diagnosed slightly more frequently than expected in aggregate (observed/expected ratio 1.086–1.104, 2015–2019) but substantially under-diagnosed in non-Hispanic Black (0.696) and Hispanic (0.758) beneficiaries compared with non-Hispanic White (1.367) (Mattke et al., Alzheimer’s Research & Therapy 2023; PMCID PMC10362635). Missed and delayed Alzheimer’s diagnosis is associated with higher rates of hospitalization, longer hospital stays, increased emergency department visits, and inappropriate medication management. Peer-reviewed speech biomarker research underlying GIA® reports AUC 0.890 for cognitive decline detection — the trajectory that includes mild cognitive impairment, Alzheimer’s disease, and related dementias. 42 CFR § 410.15(a)(v) lists detection of any cognitive impairment as a required element of the Medicare annual wellness visit.
Outpatient neurology evaluates and manages cognitive, movement, and neurodegenerative disorders referred from primary care or self-referred. Among Medicare patients referred for neurology evaluation, the average wait to first appointment is 34 days, and 18% wait longer than 90 days (AAN study, Neurology, 2025). The underlying peer-reviewed speech biomarker research reports AUC 0.97 for Parkinson's disease detection from natural conversation (Sensitivity 0.98, Specificity 0.96). GIA® delivers that structured speech-biomarker data during the encounter itself — available in the EHR before the neurologist begins the face-to-face portion of the visit.
Why Alzheimer's Disease goes undetected in outpatient neurology
A neurologist or neurology nurse practitioner conducts the patient encounter. Support staff (medical assistants or clinical staff) handle intake and vitals. Comprehensive cognitive and neurological screening competes with the chief complaint, history, exam, and care planning within the visit length. Alzheimer's Disease symptoms are often subtle, progressive, and easily attributed to other factors in this care environment.
Among Medicare patients referred for neurology evaluation, 18% wait longer than 90 days for their first appointment (average wait: 34 days; AAN study, Neurology, 2025) — primary-care referrers operate without longitudinal data on the referred patient until the visit occurs
New-patient outpatient neurology visits run 45-59 minutes (CPT 99204) or 60-74 minutes (CPT 99205); history-taking, neurological and cognitive exam, differential diagnosis, care planning, and patient education compete for the same time window
Established-patient follow-up visits at 30-39 minutes (CPT 99214) or 40-54 minutes (CPT 99215) at a 3, 6, or 12-month cadence miss interval cognitive or motor-speech changes that would inform medication titration or care-plan decisions
Formal neuropsychological testing (CPT 96132 first hour + 96133 each additional hour) is administered in a separate extended-time encounter when comprehensive cognitive characterization is warranted — adding to total time-to-evaluation across the diagnostic pathway
How does GIA® screen for Alzheimer's Disease in outpatient neurology?
GIA® meets the patient by video, voice, or landline — wherever they are in the outpatient neurology environment. The screening conversation takes 40 seconds and feels like a natural check-in, not a clinical assessment.
During the conversation, GIA® analyzes over 2,500 speech biomarkers — including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators — alongside 436 visual data points from facial micro-expressions and body movement during video sessions.
Results are delivered to the clinician in under 2 minutes. Four data types write back to the EHR automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video. The clinician reviews and submits — the human is always in the loop.
Alzheimer's Disease in outpatient neurology: the numbers.
The screening challenge
A new-patient neurology evaluation must combine history, neurological and cognitive exam, differential diagnosis, care planning, and patient education within 45-59 minutes (CPT 99204) or 60-74 minutes (CPT 99205). Formal neuropsychological testing (CPT 96132 first hour + 96133 each additional hour) is administered in a separate extended-time encounter when comprehensive cognitive characterization is warranted — it is not part of the new-patient encounter. Between scheduled visits, the specialist depends on patient self-report or primary-care follow-up, losing interval signal on progression that would inform medication titration or care-plan decisions. GIA® supplies structured cognitive and motor-speech biomarker data without consuming clinician visit time. Documentation supports billing accuracy for E/M coding; coding decisions remain with the clinical documentation and coding team.
What compliance requirements does this address?
E/M visit coding for outpatient services: CPT 99204 (45-59 min) / 99205 (60-74 min) for new patients; CPT 99214 (30-39 min) / 99215 (40-54 min) for established patients (AMA CPT 2026; CMS MLN006764). CPT 96132 (first hour) and 96133 (each additional hour) cover neuropsychological testing evaluation services when comprehensive cognitive characterization is clinically indicated. Documentation supports billing accuracy and the documented level of medical decision-making; coding decisions remain with the clinical documentation and coding team.
GIA® produces structured documentation automatically — screening results with ICD-10 codes, clinician-ready medical notes, full timestamped transcripts, and recorded patient video — all written back to the EHR in real time and available for clinical, billing, and compliance review.
Alzheimer's Disease screening in outpatient neurology
How is Alzheimer's Disease screened in outpatient neurology?
GIA® screens for Alzheimer's Disease through a single conversational interaction lasting 40 seconds. She analyzes over 2,500 speech biomarkers using Voice AI, Computer Vision, and Speech Biomarkers. GIA® screens during rooming or in the waiting area before the neurologist enters — capturing structured cognitive, motor-speech, and behavioral biomarker data that the specialist reviews alongside the patient's history and exam. The 40-second conversation produces results in under two minutes, available in the EHR before the face-to-face portion of the visit begins. Results are delivered to the clinician in under 2 minutes.
Does Alzheimer's Disease screening require additional staff?
No. GIA® conducts the screening conversation independently — zero additional clinical staff required during the interaction. A neurologist or neurology nurse practitioner conducts the patient encounter. Support staff (medical assistants or clinical staff) handle intake and vitals. Comprehensive cognitive and neurological screening competes with the chief complaint, history, exam, and care planning within the visit length. The clinician reviews the results in under 2 minutes.
What is the accuracy of Alzheimer's Disease screening?
Alzheimer's Disease screening accuracy: Clinically validated vocal biomarker screening. The platform is peer-reviewed across 19 published studies and trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events.
How does GIA® fit into the neurology visit workflow?
GIA® screens during rooming or in the waiting area before the neurologist enters. The 40-second conversation produces structured cognitive, motor-speech, and behavioral biomarker results in under two minutes — available in the EHR for the neurologist to review alongside the patient's history and exam during the face-to-face encounter.
How does GIA® support documentation for outpatient E/M coding (99204 / 99205 / 99214 / 99215)?
GIA® writes structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video back to the EHR in real time. That documentation contributes to the level of medical decision-making documented in support of E/M coding (99204 / 99205 for new patients; 99214 / 99215 for established patients). Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
Can GIA® be used between scheduled neurology visits to monitor progression?
Yes. GIA® can be administered by phone, landline, or video between scheduled visits — capturing interval changes in speech biomarkers that signal cognitive or motor-speech progression. Results write back to the EHR for clinician review at the next visit, or asynchronously if the change is clinically significant.
How does GIA® relate to formal neuropsychological testing (CPT 96132 / 96133)?
GIA® is a screening tool, not a neuropsychological battery. It surfaces structured risk signals from speech and behavioral biomarkers in 40 seconds. Formal neuropsychological evaluation (CPT 96132 first hour + 96133 each additional hour) remains the appropriate next step when GIA® or other screening evidence warrants comprehensive cognitive characterization. The clinician determines when formal testing is indicated.
How does GIA® screen for Alzheimer’s disease?
GIA® analyzes 2,500+ speech biomarkers — including word-finding latency, semantic coherence, processing speed, articulation, and prosodic markers associated with cognitive change — during a natural conversation lasting 40 seconds. Peer-reviewed biomarker accuracy for cognitive decline detection (the trajectory that includes mild cognitive impairment, Alzheimer’s disease, and related dementias) is AUC 0.890. Results write back to the EHR with structured notes for clinician review. A clinician reviews and approves every result before it enters the clinical record.
Why is Alzheimer’s underdetected and underdocumented in primary care?
A 2011 meta-analysis of 15 dementia studies (Mitchell, Meader, Pentzek, Acta Psychiatrica Scandinavica) found GPs recognized 73.4% of dementia cases by clinical judgment but documented the recognition in medical records only 37.9% of the time. Contemporary US Medicare data (Mattke et al., Alzheimer’s Research & Therapy 2023) show dementia is over-diagnosed in aggregate but substantially under-diagnosed in non-Hispanic Black (detection ratio 0.696) and Hispanic (0.758) beneficiaries versus non-Hispanic White (1.367). Non-memory presentations of early Alzheimer’s — executive dysfunction, behavioral change, sleep disturbance — are commonly cited contributors to missed detection.
How does GIA® support cognitive-impairment detection at the annual wellness visit?
42 CFR § 410.15(a)(v) lists detection of any cognitive impairment as a required element of both the initial and subsequent Medicare annual wellness visits. GIA® delivers a structured speech-biomarker-based screen in 40 seconds — operationally compatible with the AWV visit envelope — and writes results back to the EHR for clinician review. The same 40-second screening also supports depression risk-factor review under § 410.15(a)(vi). Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
Does GIA® diagnose Alzheimer’s disease?
No. GIA® screens — she does not diagnose. She surfaces structured risk signals from speech biomarker analysis for clinician review. The clinician applies clinical judgment, reviews additional data (cognitive history, neuropsychological testing, neuroimaging, biomarkers, family history, functional assessment), and makes any diagnostic determination, including the differential between Alzheimer’s disease and other dementia etiologies. GIA® is a clinical decision support tool with mandatory clinician-in-the-loop review on every result.
What is the limitation of standard Alzheimer’s screening tools in primary care?
The MMSE, MoCA, SLUMS, and Mini-Cog all require trained clinician administration and 5 to 30 minutes per patient. The MMSE has well-documented ceiling effects in early disease and weak coverage of executive function. The MoCA is more sensitive but requires more clinician time. Sensory deficits, language differences, and patient fatigue further compromise reliability. None of these instruments is well-suited to detecting the non-memory-dominant presentations of early Alzheimer’s. GIA® analyzes speech biomarkers across multiple cognitive domains from natural conversation without requiring clinician administration time or instrument-specific selection.
Alzheimer's Disease screening in other care settings
Other conditions screened in outpatient neurology
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
See GIA® screen for Alzheimer's Disease live
40 seconds. 60-second results. Zero staff time.